Me Medicine vs. We Medicine : : Reclaiming Biotechnology for the Common Good / / Donna Dickenson.

Personalized healthcare-or what the award-winning author Donna Dickenson calls "Me Medicine"-is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, priv...

Full description

Saved in:
Bibliographic Details
Superior document:Title is part of eBook package: De Gruyter Columbia University Press eBook-Package Backlist 2000-2013
VerfasserIn:
Place / Publishing House:New York, NY : : Columbia University Press, , [2013]
©2013
Year of Publication:2013
Language:English
Online Access:
Physical Description:1 online resource (296 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05206nam a22007575i 4500
001 9780231534413
003 DE-B1597
005 20220302035458.0
006 m|||||o||d||||||||
007 cr || ||||||||
008 220302t20132013nyu fo d z eng d
010 |a 2012037582 
020 |a 9780231534413 
024 7 |a 10.7312/dick15974  |2 doi 
035 |a (DE-B1597)458800 
035 |a (OCoLC)979573845 
040 |a DE-B1597  |b eng  |c DE-B1597  |e rda 
041 0 |a eng 
044 |a nyu  |c US-NY 
050 0 0 |a RA427.25  |b .D53 2013 
050 4 |a RA427.25 
072 7 |a MED050000  |2 bisacsh 
082 0 4 |a 174.2  |2 23 
100 1 |a Dickenson, Donna,   |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Me Medicine vs. We Medicine :  |b Reclaiming Biotechnology for the Common Good /  |c Donna Dickenson. 
264 1 |a New York, NY :   |b Columbia University Press,   |c [2013] 
264 4 |c ©2013 
300 |a 1 online resource (296 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 0 |t Frontmatter --   |t CONTENTS --   |t PREFACE --   |t 1. A Reality Check for Personalized Medicine --   |t 2. "Your Genetic Information Should Be Controlled by You" --   |t 3. Pharmacogenetics: One Patient, One Drug? --   |t 4. "Your Birth Day Gift " --   |t 5. Enhancement Technologies --   |t 6. "The Ancient, Useless, Dangerous, and Filthy Rite of Vaccination" --   |t 7. Reclaiming Biotechnology for the Common Good --   |t Notes --   |t References --   |t Index 
506 0 |a restricted access  |u http://purl.org/coar/access_right/c_16ec  |f online access with authorization  |2 star 
520 |a Personalized healthcare-or what the award-winning author Donna Dickenson calls "Me Medicine"-is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before-and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology. 
530 |a Issued also in print. 
538 |a Mode of access: Internet via World Wide Web. 
546 |a In English. 
588 0 |a Description based on online resource; title from PDF title page (publisher's Web site, viewed 02. Mrz 2022) 
650 0 |a Biotechnology  |x Ethics. 
650 0 |a Biotechnology  |x Moral and ethical aspects. 
650 0 |a Medicine, Preventive  |x Moral and ethical aspects. 
650 0 |a Patient-centered health care  |x Moral and ethical aspects. 
650 0 |a Personalized medicine  |x Ethics. 
650 0 |a Public Health Practice  |x ethics. 
650 7 |a MEDICAL / Ethics.  |2 bisacsh 
773 0 8 |i Title is part of eBook package:  |d De Gruyter  |t Columbia University Press eBook-Package Backlist 2000-2013  |z 9783110442472 
776 0 |c print  |z 9780231159753 
856 4 0 |u https://doi.org/10.7312/dick15974 
856 4 0 |u https://www.degruyter.com/isbn/9780231534413 
856 4 2 |3 Cover  |u https://www.degruyter.com/document/cover/isbn/9780231534413/original 
912 |a 978-3-11-044247-2 Columbia University Press eBook-Package Backlist 2000-2013  |c 2000  |d 2013 
912 |a EBA_BACKALL 
912 |a EBA_CL_MDPM 
912 |a EBA_EBACKALL 
912 |a EBA_EBKALL 
912 |a EBA_ECL_MDPM 
912 |a EBA_EEBKALL 
912 |a EBA_ESTMALL 
912 |a EBA_PPALL 
912 |a EBA_STMALL 
912 |a GBV-deGruyter-alles 
912 |a PDA12STME 
912 |a PDA13ENGE 
912 |a PDA18STMEE 
912 |a PDA5EBK